<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="85683">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01925950</url>
  </required_header>
  <id_info>
    <org_study_id>BDP-GVHD-08</org_study_id>
    <nct_id>NCT01925950</nct_id>
  </id_info>
  <brief_title>Study of orBec® as Monotherapy in the Treatment of Patients With Upper GI Symptoms Caused by Chronic Graft Versus Host Disease (GVHD)</brief_title>
  <official_title>A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of the Safety and Efficacy of orBec® (Oral Beclomethasone 17,21-Dipropionate) Administered as Monotherapy in the Treatment of Upper Gastrointestinal (GI) Symptoms Caused by GVHD in Patients With Chronic GI GVHD</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Soligenix</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Soligenix</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Use of an oral topically-active glucocorticoid with limited side effects may control the
      gastrointestinal inflammatory process of GVHD and minimize glucocorticoid exposure.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>December 2013</start_date>
  <completion_date type="Anticipated">April 2016</completion_date>
  <primary_completion_date type="Anticipated">April 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>GI GVHD symptoms</measure>
    <time_frame>16 weeks</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Chronic Gastrointestinal Graft vs Host Disease</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Control</description>
  </arm_group>
  <arm_group>
    <arm_group_label>orBec</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Investigational drug</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>orBec</intervention_name>
    <arm_group_label>orBec</arm_group_label>
    <other_name>oral BDP</other_name>
    <other_name>oral beclomethasone 17,21-dipropionate</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Receipt of allogeneic hematopoietic cell transplant &gt;100 days prior to consent

          -  Documented cGVHD as defined by the NIH consensus criteria in at least one organ
             system other than the GI tract (for example, cGVHD of the oral cavity would qualify
             as a criterion)

          -  Endoscopic findings consistent with GI GVHD

          -  Must be able to swallow tablets

          -  Must be able to read and understand informed consent

          -  Adequate birth control methods for the duration of the study

        Exclusion Criteria:

          -  &gt;500 mL/day of diarrhea on any 1 day within 3 days prior to the first dose of study
             drug

          -  GI infection

          -  Multi-organ failure or other condition that, in the opinion of the investigator,
             would compromise the patient's ability to complete the study.

          -  HIV seropositivity

          -  Pregnant or nursing female

          -  Use of any investigational drug to treat chronic GVHD within 28 days of the first
             dose of study drug

          -  Evidence of recurrent or progressing malignant disorder that was the indication for
             HCT
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Adam Rumage</last_name>
    <phone>609-538-8200</phone>
  </overall_contact>
  <location>
    <facility>
      <name>John Theurer Cancer Center</name>
      <address>
        <city>Hackensack</city>
        <state>New Jersey</state>
        <zip>07601</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Vanderbilt-Ingram Cancer Center</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2014</verification_date>
  <lastchanged_date>January 7, 2014</lastchanged_date>
  <firstreceived_date>August 16, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>BDP</keyword>
  <keyword>orBec</keyword>
  <keyword>GVHD</keyword>
  <keyword>beclomethasone dipropionate</keyword>
  <keyword>bone marrow transplant</keyword>
  <keyword>hematopoietic cell transplant</keyword>
  <keyword>HCT</keyword>
  <keyword>stem cell transplant</keyword>
  <keyword>marrow transplant</keyword>
  <keyword>SCT</keyword>
  <keyword>beclomethasone 17,21-dipropionate</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Graft vs Host Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Beclomethasone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
